BioLum Sciences is a pioneering company in the bioanalytical chemistry and medical device sector, focusing on chronic disease management. The company operates in the healthcare market, serving patients with chronic respiratory and cardiovascular conditions such as asthma, COPD, hypertension, and heart failure. BioLum Sciences has developed a novel, low-cost platform that measures biomarkers found in exhaled breath condensate (EBC) and blood. This proprietary technology allows users to monitor treatment progression in real time on desktop computers or mobile devices. The platform also provides researchers and clinicians with tools to develop personalized treatments based on specific inflammatory profiles, thereby optimizing therapy and improving patient quality of life. The business model revolves around providing these advanced diagnostic tools to healthcare providers and researchers, generating revenue through the sale of its technology and related services. However, it is important to note that BioLum's technology has not yet received FDA clearance and is not yet available for sale.

Keywords: bioanalytical chemistry, medical device, chronic disease, respiratory, cardiovascular, biomarkers, real-time monitoring, personalized treatment, healthcare, diagnostics.